Get the Stockscreener App
62.97
0.70%
-0.14
Uniqure N V stock is traded at $62.97, with a volume of 1.30M.
It is down -0.70% in the last 24 hours and up +331.17% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$62.83
Open:
$62.99
24h Volume:
1.30M
Relative Volume:
0.42
Market Cap:
$3.44B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-16.06
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
-1.98%
1M Performance:
+331.17%
6M Performance:
+564.43%
1Y Performance:
+864.30%
1-Day Range:
$61.90
$65.14
1-Week Range:
$58.12
$65.14
52-Week Range:
$5.35
$65.14
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
62.75 | 3.63B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.20 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
484.92 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
830.97 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.57 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure N.V. stock outlook for YEARTrend Reversal & Expert Verified Stock Movement Alerts - newser.com
Using Bollinger Bands to evaluate uniQure N.V.2025 Market Outlook & Expert Curated Trade Setups - newser.com
Can uniQure N.V. stock hit analyst price targetsLong Setup & Risk Controlled Swing Alerts - newser.com
Is uniQure N.V. stock trading at a premium valuationWeekly Market Summary & Real-Time Market Sentiment Reports - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
How institutional buying supports uniQure N.V. stockMarket Movers & Real-Time Chart Breakout Alerts - newser.com
What catalysts could drive uniQure N.V. stock higher2025 Top Decliners & Technical Pattern Recognition Alerts - newser.com
uniQure N.V. $QURE Shares Purchased by Aberdeen Group plc - MarketBeat
uniQure NV Hits New 52-Week High of $61.79, Surging 1014.68% - Markets Mojo
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is uniQure’s Rally Justified After Positive Huntington’s Disease Therapy Data? - Yahoo Finance
Jim Cramer on uniQure: “This One Has Too Many Questions for Me Up Here” - MSN
Trend analysis for uniQure N.V. this week2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Will uniQure N.V. see short term momentumBreakout Watch & Verified Technical Trade Signals - newser.com
uniQure N.V. (QURE) Stock Report: A Look at Strong Buy Ratings Amidst Clinical Advancements - DirectorsTalk Interviews
Will uniQure N.V. (UQ1) stock beat value stocksDay Trade & AI Powered Market Trend Analysis - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat
Is uniQure’s Stock Poised for a Comeback? - StocksToTrade
Price momentum metrics for uniQure N.V. explainedBreakout Watch & Technical Entry and Exit Tips - newser.com
Developing predictive dashboards with uniQure N.V. dataWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind - insights.citeline.com
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha
uniQure NV Hits Day High with 9.47% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (NASDAQ:QURE) Sets New 12-Month HighTime to Buy? - MarketBeat
Uniqure NV stock hits 52-week high at 60.84 USD By Investing.com - Investing.com Nigeria
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛
Uniqure NV stock hits 52-week high at 60.84 USD - Investing.com
United States Adeno-Associated Virus (AAV) Vectors - openPR.com
HC Wainwright Analysts Lift Earnings Estimates for uniQure - MarketBeat
UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com
uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat
HC Wainwright Issues Positive Forecast for uniQure Earnings - MarketBeat
uniQure’s Huntington’s gene therapy holds blockbuster potential, says analyst - The Pharma Letter
Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding - Sahm
uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure stock price target raised to $110 from $70 at H.C. Wainwright - Investing.com
uniQure (QURE) Receives Boosted Price Target from HC Wainwright & Co. | QURE Stock News - GuruFocus
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
3.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):